newsfilter
← Latest News
Business Wire·

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapy Median overall survival of 12.3 months in a heavily pretreated population with poor